San Diego, Calif. – UC San Diego Health is the first health system in San Diego County to offer a new bladder-saving gene therapy to treat localized bladder cancer. The novel treatment is the first and only FDA-approved gene therapy delivered directly into the bladder for non-muscle-invasive bladder cancer (NMIBC)....
Latest News
San Diego, California – In a recent study, researchers at the University of California, San Diego, have provided new insights into the central role of goblet cells—specialized cells that line the gut—in maintaining a healthy and balanced immune environment within the gastrointestinal (GI) tract. Led by Dr Fernanda Raya Tonetti,...
San Francisco, Calif. – In a discovery that opens the door to a less invasive way of treating some serious disorders before birth, UC San Francisco scientists have found that delivering medicine through amniotic fluid is as effective as delivering it to the fetal brain via cerebrospinal fluid. The experiment...
San Francisco, Calif. – A Smart Molecule Beats the Mutation Behind Most Pancreatic Cancer. Scientists at UCSF have discovered a new way to disarm a deadly protein that also appears in cancers of the lung, breast and colon. The new molecule permanently modifies a wily cancer-causing mutation, called K-Ras G12D,...
Milan, Italy: Researchers have developed a genetic test that can identify how patients with triple negative early-stage breast cancer will respond to immunotherapy drugs. This means that patients who are unlikely to respond to these drugs can avoid the adverse side effects associated with them and can be treated with...
San Francisco, Calif. – In a discovery that could hasten treatment for patients with multiple sclerosis (MS), UC San Francisco scientists have discovered a harbinger in the blood of some people who later went on to develop the disease. In about 1 in 10 cases of MS, the body begins...
San Francisco, Calif. – Combining testosterone-blocking drugs in patients with prostate cancer relapse prevents the spread of cancer better than treatment with a single drug, a multi-institution, Phase 3 clinical trial led by UC San Francisco researchers has found. The approach can extend the time between debilitating drug treatments without...
Santa Barbara, Calif. — UC Santa Barbara researchers and collaborators in Colombia, Brazil and Germany are progressing toward an understanding of mechanisms that underlie Alzheimer’s disease, in particular an early-onset, genetic form that has afflicted generations of an extended family in Colombia. They also shed some light on a woman...
Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activity DZP showed consistent improvements in fatigue, a common and debilitating symptom of systemic lupus erythematosus (SLE) At Week 48, more individuals receiving DZP experienced no or low disease activity...
ATLANTA, GA — UCB, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for BIMZELX® (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). In addition, a second sBLA...